3 unknown, 1 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 3, Completed 1 |
| Phase 2 | 2 | Unknown 2 |
Follow Hepatic Carcinoma: new trials by email Literature Review of Hepatic Carcinoma trials Research Report on Hepatic Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs Tumor infiltrating lymphocyte - Hepatic Carcinoma | Phase 1 / Phase 2 | Unknown | CAR-T (Shanghai) Cell Biotechnology Co., Ltd. | 40 | 2020-08-26 | 2020-09-04 |
| Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. Sintilimab, Microwave Ablation, TACE - Hepatic Carcinoma | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 45 | 2020-01-01 | 2024-08-01 |
| A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer CAR-T cell immunotherapy - Colon Cancer, Esophageal Carcinoma | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital of Chengdu Medical College | 60 | 2017-01-01 | 2017-01-06 |
| Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma H3B-6527 - Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 1 | Completed | H3 Biomedicine Inc. | 128 | 2016-12-28 | 2023-11-13 |
Carcinoma, Hepatocellular (4) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Adenocarcinoma (4) · Carcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Liver Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Liver Neoplasms (3) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1)
H3B-6527 (1) · Immunotherapy, Adoptive (1) · sintilimab (1)
CAR-T (Shanghai) Cell Biotechnology Co., Ltd. (1) · First Affiliated Hospital of Chengdu Medical College (1) · H3 Biomedicine Inc. (1) · Shanghai Zhongshan Hospital (1)
China (3) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Russia (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Xiao-an Li, PhD (1)
2016 (1)